| :: trillium therapeutics |
15, 2011 /CNW/ -Trillium Therapeutics Inc., a privately-held biopharmaceutical firm building exclusive and innovative biologic therapies,
Dr. Underdown's past and current board positions include: ID Biomedical, Trillium Therapeutics, Cytochroma Inc. Argos Therapeutics, Nysa Membrane
2Trillium Therapeutics Inc., Toronto, ON, Canada. Suppression of patients' T-cells is a key event in CLL pathogenesis and was demonstrated to
Trillium Therapeutics, a biopharmaceutical company, has entered into a definitive licensing agreement with Biogen Idec, granting the latter
Financial interest and/or other relationship with Medtronic, Boston Scientific, Indevus, Allergan, Pfizer and Trillium Therapeutics. Conducted this research while
Canada's Voice For Biotechnology. Who We Are · Overview
20 Oct 2010 science companies including Amorfix Life Sciences, Trillium Therapeutics and Lorus Therapeutics. He has also consulted for numerous firms
Trillium Therapeutics Inc. (TTI), a Toronto-based biopharmaceutical company, announced that it has acquired all assets belonging to Arthron Ltd. Pty.,
Trillium Therapeutics - Product Pipeline Review - Q4 2010 Summary Global Market Direct's pharmaceuticals report, "Trillium Therapeutics - Product Pipeline
Results 1 - 10 of 35 Directory of patents invented by Reginald M Gorczynski (35
Trillium Therapeutics is a focused on the research and development of therapies for immune-mediated disorders.
Individual Life Insurance. Debbie Killens · Trillium Therapeutics Inc. ROFF Logistics Inc. Tenet Computer Group · Ira Wolfe
IAF · Turning up the Heat: MaRS' Investment Accelerator Fund announces 8 summer investments. Who said summers are a slow time? It definitely has not been
Trillium Therapeutics, Inc., a Toronto, Canada-based biopharmaceutical company specializing in the development of innovative therapies for
Arthron controls a large estate of intellectual property related to the activating receptor FcyRIIa.
Trillium Therapeutics Inc is a research and development company developing therapies that restore balance to the immune system in conditions associated with
Trillium Therapeutics (Canada) early-stage company focused on the development of therapies for the treatment of immune-mediated disorders,
Trillium Therapeutics, a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of
( Massachusetts) (BIIB) Enter into Global License Agreement Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in
ImmunoVaccine Technologies; Medicure Inc. Theratechnologies; Transition Therapeutics Inc. Trillium Therapeutics. Canada plays a key role in the global
Trillium Therapeutics, Inc., Toronto, Ontario, Canada. Email: Egle Funded by. Arthritis Research Campaign; Trillium Therapeutics, Inc
Trillium Therapeutics intends to new funds to advance its lead program, TTI-1612 , into clinical trials for the treatment of interstitial cystitis (IC),
Violetta Kubiak, Trillium Therapeutics, Etobicoke, ON - Business Contact Information in Jigsaw's business directory. Jigsaw's business directory provides
TRILLIUM THERAPEUTICS INC. Patent applications. Patent application number, Title, Published. 20110206668, METHODS AND COMPOSITIONS FOR
Recipient Name: TRILLIUM THERAPEUTICS INC. Location: ETOBICOKE, ON, CA. Date: 2006-09-27. Value: $ 122000.00. Type: Contribution
He serves on the boards of a number of private and public companies, was founding Chair of Trillium Therapeutics and was chair of Verio
Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of
TORONTO, CANADA -- December 19, 2006 - Trillium Therapeutics Inc. today announced that its gastrointestinal product, TTI-1612, has been designated an
Assignee: TRILLIUM THERAPEUTICS INC (96 Skyway Avenue, Toronto, Ontario M9W 4Y9, CA) HOGARTH, Phillip, Mark (6 Robertson Street,
trillium therapeutics inc ebook books Download Looking for : trillium therapeutics inc trillium therapeutics inc.pdf download trillium therapeutics inc. doc
Overview page of events, news, people, companies, organizations related to Trillium Therapeutics Inc.
Get Trillium Therapeutics business contacts for Healthcare, Pharmaceuticals, & Biotech lead generation, b2b marketing and sales prospecting. All business
Trillium Therapeutics Inc. company information, data and profile. Benchmark the business against its key industry competitors.
Dr Moore is currently Chairman of Trillium Therapeutics Inc, a private Toronto- based biologics company, and of Myotec Limited, a speciality pharma company
Trillium Therapeutics Inc. - Product Pipeline Review - Q4 2010 Trillium Therapeutics Inc. - Product Pipeline Review - Q4 2010 Summary Global
Free Online Library: Gastrointestinal Product from Trillium Therapeutics Granted Orphan Drug Status in U.S., Europe. by "SciTech21"; Science and technology,
Trillium Therapeutics Inc company profile in Etobicoke, Canada. Our company profile report for Trillium Therapeutics Inc includes business information such as
2006 - Rimon Therapeutics Ltd. 2005 - ImmunoVaccine Technologies Inc., Halifax, NS 2005 - Trillium Therapeutics Inc., Toronto, ON 2004 - Arc Pharmaceuticals
Trillium Therapeutics Inc. is a private biopharmaceutical companyspecializing in innovative therapies of immune-mediated conditions, such
16 May 2011 with GlaxoSmithKline, Johnson & Johnson, Pfizer, Watson, Taris Biomedical, Ferring, Farr Labs, Triton, Trillium Therapeutics and Astellas.
Results 1 - 10 of 54 Assignee(s): TRILLIUM THERAPEUTICS INC | Inventor(s): GORCZYNSKI M + 1. TRILLIUM THERAPEUTICS INC View patent details for
Company Description, Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the
Dr. Niclas Stiernholm, Chief Executive Officer of funding-recipient Trillium Therapeutics Inc., said: “This new round of financing is pivotal,
TORONTO, December 14 /PRNewswire/ -- Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, announced today that it has entered into an
Dr. Craig Binnie, an associate with Alba, was most recently Director of Drug Development, Trillium Therapeutics in Toronto, a developer of novel recombinant
Trillium Therapeutics Inc. or TTI announced that it has entered into a definitive license agreement with Biogen Idec (BIIB), granting the latter
TORONTO (CP) - Trillium Therapeutics Inc., a private firm specializing in immune system therapies, said Thursday it has acquired Arthron Ltd.
TORONTO, Nov. 5 /CNW/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr.
Trillium Therapeutics specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company's
He currently serves as Chairman of the Board of Argos Therapeutics Inc. ( Durham . Trillium Therapeutics and Cytochroma Inc. He has been actively involved in
Trillium Therapeutics, a privately-held Canadian biopharmaceutical company specializing in the development of innovative therapies for the
Trillium Therapeutics Inc. is a private Trillium secures additional financing on the strength of lead program and proprietary position around
Trillium Therapeutics Inc., a privately-held biopharmaceutical company specializing in the development of innovative therapies for the treatment
Lily currently sits as a Director on the Boards of BTE Technologies Inc., Interface Biologics Inc., Trillium Therapeutics Inc., Cytochroma Inc.,
What is the meaning of TRILLIUM THERAPEUTICS INC acronym/abbreviation and what does TRILLIUM THERAPEUTICS INC stand for? Get the Definition of
Dr Michael Moore PhD, DSc, FRCpath, former Piramed Chief Executive, Chairman of Trillium Therapeutics, joins the Chronos Therapeutics' Board of Directors.
Browse by: INVENTOR · PATENT HOLDER · PATENT
CEO, Trillium Therapeutics Inc. CEO of Trillium Therapeutics Inc. [TTI], a privately held Canadian biopharmaceutical company, Dr. Niclas Stiernholm has raised
Get to know Trillium Therapeutics Inc. CEO & other corporate executives. Learn about the Board of Directors, Executive Committees and CEO
Funding Support from Arthritis Research Campaign, Kennedy Institute of Rheumatology Trustees, Trillium Therapeutics Inc, Nuon Therapeutics Inc, which is
The Biotech Career Center is a portal for scientists seeking career advancement with hundreds of up to date job listings as well as a job search
Private Equity Hub (peHub) is an interactive forum for the private equity community, which includes venture capitalists, buyouts professionals, attorneys, bankers,
Trillium Therapeutics Inc. has entered into two definitive license agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids)
Trillium Therapeutics Inc. (TTI) is a private research and development biopharmaceutical company with two main areas of focus: cytoprotection and immune
Trillium Therapeutics Inc. (TTI) - StumbleUpon. Trillium Therapeutics Inc. (TTI) · Trillium Therapeutics Inc. (TTI). Discovered on Jul 19, 01:
Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative biologic therapies, today
Stem Cell Therapeutics Corp. is a biotechnology company focused on the Rimon Therapeutics Ltd, Trillium Therapeutics Inc and YM BioSciences Inc.
Jin: Trillium Therapeutics Inc. (TTI): Patents & Royalties, Research Funding. Dick: Trillium Therapeutics Inc. (TTI): Patents & Royalties,
The Canadian Life Sciences Database provides a comprehensive overview on the life sciences industry in Canada with a special focus on biotechnology and
Trillium Therapeutics Inc. to Commence Clinical Testing of TTI-1612 Full story: BioSpace. The company has recently received a No Objection
Current R&D Portfolio of Trillium Therapeutics Inc.; Trillium Therapeutics Inc. - Key Therapeutics; Trillium Therapeutics Inc. - Pipeline Overview and.
Trillium Therapeutics Inc. (TTI) is a private research and development company that develops therapies that restore balance to the immune system in conditions
of private and public companies, was founding Chair of Trillium Therapeutics and was chair of. Verio Therapeutics, a Canadian stem cell
Today, the Trillium Waverly Children's Programs (including day treatment and therapeutic school programs, outpatient therapy, and most of Trillium's
Trillium Therapeutics Inc.-Company Report - research report released Trillium Therapeutics Inc.-Company Report.
BioWorld Online is the news service of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date
Lily currently sits as a Director on the Boards of BTE Technologies Inc., Interface Biologics Inc., Trillium Therapeutics Inc., Cytochroma Inc., Zelos Therapeutics
Want to like this page? To interact with Trillium Therapeutics you need to sign up for Facebook first. Sign Up. It's free and anyone can join. Already a member?
Trillium Therapeutics and Medarex Announce Collaboration to Develop Fully Human Antibody TherapeuticsToronto, Ontario and Princeton,
Trillium Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical,
Global Market Direct's pharmaceuticals report, "Trillium Therapeutics - Product Pipeline Review - Q4 2010" provides data on the company's
She is currently on the boards of Aegera Therapeutics, Axela, Cytochroma, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics.
Trillium Therapeutics Inc. Product Pipeline Review Q4 2010 Summary Global Market Direct s pharmaceuticals report, Trillium Therapeutics Inc. - Product
Trillium Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical, biotechnology and
ID Biomedical, Nysa Membrane Technologies, Trillium Therapeutics,
Company Name, Trillium Therapeutics Inc. Information Release Date, 9/18/2008. Transaction Type, Venture Equity. Amount, $12000000
Lily currently sits as a Director on the Boards of BTE Technologies Inc., Interface
Form an independent opinion about Trillium Therapeutics, Inc.´s growth strategies through the organic and inorganic activities undertaken
What is the overall size of the therapeutic area, and how do various Trillium Therapeutics; - UCB; - Warner Chilcott; - Wyeth; - Zenyaku Kogyo; - Zymogenetics
OB, SNY, Soligenix, Trillium therapeutics, VentiRx Pharma, ZGEN, CELG Celgene Celldex Therapeutics Cell Therapeutics CEPH Cephalon
Trillium Therapeutics Inc. to Commence Clinical Testing of TTI-1612 in Patients Trillium Therapeutics Inc. Strengthens its Board of Directors 11/5/2008 2:34:35
Trillium Therapeutics Inc. - Product Pipeline Review - Q4 2010 Trillium Therapeutics Inc. - Product Pipeline Review - Q4 2010 Summary Global Market
TORONTO, May 12 /CNW/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1
Trillium Therapeutics Inc. company research & investing information. Find executives and the latest company news.
Life Science Analytics :: Trillium Therapeutics Inc.-Detailed Product Pipeline :: July 2010 :: Pharmaceutical market research report.
Trillium Therapeutics will initiate a phase I clinical trial of its experimental drug, TTI-1612, in patients with interstitial cystitis/bladder pain
Niclas Stiernholm, Chief Executive Officer, Trillium Therapeutics Inc. (TTI) of Trillium Therapeutics Inc. (TTI)''s information - including email, business address,
Korean pharmaceutical companies Pharmaceutical pharmaceutical company pharmaceutical licensing pharmaceutical research medicine
Trillium Therapeutics and Biogen Idec enter global license agreement. Posted on 12 January 2010. TTI will receive an upfront payment and is eligible to receive
Dr. Berendt is currently a director of Waters Corporation and Trillium Therapeutics Inc., and has served on the board of directors of a number of companies
Director, Drug Development at Trillium Therapeutics, Inc. Director, Regulatory Affairs and Manufacturing at Transition Therapeutics, Inc Director, Clinical Product
Trillium Therapeutics. Fc receptor-modulating compounds and compositions. WO 2006028956. Genentech. Anti-FcγRIIb antibody and uses thereof. 5A6/22E7
Trillium launches phase I IC/BPS study. Trillium Therapeutics will begin a phase I clinical trial of its experimental drug, TTI-1612, in patients with
Trillium Therapeutics Inc Biotech Investors Financing Canada Capital Partners Inc Life Sciences MARKHAM VenGrowth Toronto Katabi Hockey Location INC
Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology
About Trillium Therapeutics Inc., Trillium Therapeutics Inc. (TTI), a research- driven biopharmaceutical company with a strong immunology focus, specializes in
View Trillium Therapeutics's competitors and companies similar to Trillium Therapeutics. Competitors to Trillium Therapeutics include - Acorda, Aeson
On behalf of the management and staff of Trillium Therapeutics Inc. we would like to express our thanks and gratitude to CSE for their excellent service and
Company profile for Trillium Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales,
TORONTO, Jan. 28 /PRNewswire/ - Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics,
Mohamed Sayegh, President, Trillium Therapeutics Inc. (TTI) of Trillium Therapeutics Inc. (TTI)''s information - including email, business address, business
Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation.
Inventors: GORCZYNSKI; REGINALD M.; (Willowdale, CA) ; CLARK; DAVID A.; ( Burlington, CA). Assignee: TRILLIUM THERAPEUTICS INC.
and as a member of the Scientific Advisory Boards of the Vengrowth Life Sciences Fund, and Trillium Therapeutics. He is also a member of the Advisory Board
Trillium Therapeutics Inc. (Trillium), a biopharmaceutical company, announced that it will begin a Phase I clinical trial of its experimental drug,
Trillium Therapeutics Inc. Global Public & Private Company Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as
Trillium Therapeutics will begin a phase I clinical trial of its experimental drug, TTI -1612, in patients with interstitial cystitis/bladder pain
From finding safer ways to create therapeutic stem cells, to world-class responses to Theratechnologies; Transition Therapeutics Inc. Trillium Therapeutics
Biotech and pharmaceutical companies in Toronto, Ontario.
Aegera Oncology Inc. 23.3. Biotechnology. Cytochroma Canada Inc. 22.9. Biotechnology. Zelos Therapeutics Inc. 22.1. Biotechnology. Trillium Therapeutics Inc.
Trillium Therapeutics Inc. (TTI) is a privately-owned, Toronto-based biopharmaceutical company with two main areas of focus: cytoprotection and immune
Trillium Therapeutics (Canada) a preclinical-stage biopharmaceutical company focused on interstitial cystitis, closed a $1M Series A financing.
{If Trillium. Therapeutics Inc. June [0, 2005. Mr. Phil Bradley and Staff, On behalf of the management and staff of Trillium Therapeutics Inc. we would like to
01-15-2010: Trillium Therapeutics Inc. (TTI) announced that it has entered into a definitive license agreement with Biogen Idec, granting the latter exclusive
Trillium Therapeutics. Necrotizing enterocolitis (NEC) in preterm infants. Toronto, ON. Caprion Proteomics. Shiga-toxin producing bacterial infection. Montreal
Dr. Niclas Stiernholm has been the CEO of Trillium Therapeutics Inc., a leading Canadian immunology company, since 2002. Trillium has a demonstrated ability
TORONTO, Oct. 6, 2005 (Canada NewsWire via COMTEX) -- Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, today
Company profile for Trillium Therapeutics Inc. in Toronto,ON. Get accurate business information including key contacts, company financials and more in the
Die Datenbank für Pressematerial in Text, Bild, Video und Ton von mehr als 15.000 Pressestellen aus Wirtschaft, Industrie, Politik, Sport und Kultur.
19 /PRNewswire/ - Trillium Therapeutics Inc. (Trillium) today announced that its gastrointestinal product, TTI-1612, has been designated an Orphan Drug by the
12 /CNW/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced
BDC Capital GrowthWorks Capital Vengrowth Private Equity Partners Biopharmaceutical company Trillium Therapeutics Inc. has closed on $1 million in equity
Title: Director, Drug Development at Trillium Therapeutics Inc. Demographic info: Toronto, Canada Area | Biotechnology. Current: Director, Drug Development at
Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor.
Trillium Therapeutics, University of Montreal deal. print; bookmark; archives Trillium Therapeutics Inc., Toronto, Ontario. 6 words displayed of
Trillium Therapeutics Inc.-Therapeutic Competitors Report Report includes a business summary, tabular representation of the number and percentage of
May 12, 2011, Trillium Raises Funds to Advance Urology Program Into Clinical Trials, Trillium Therapeutics. December 02, 2010, Trillium's Cancer Stem Cell
Trillium Therapeutics: TTI was founded in 1996 as Transplantation Technologies Inc. (TTI) by five research scientists and six research institutions located in
Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery
On January 12, 2010, Trillium Therapeutics Inc., a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions
Watch Trillium Therapeutics Inc. Videos. Free Streaming Trillium Therapeutics Inc . Video Clips.
Dr. Niclas Stiernholm is Independent Director of Stem Cell Therapeutics Corp., with effect from July 18, 2011. He has been the CEO of Trillium Therapeutics Inc.,
OneMedPlace - The latest innovations in health and medicine.
Tracon Pharmaceuticals; Transgene; Trillium Therapeutics; Trion Pharma; UCB
He has also been involved in translation of his research, being co-founder of Trillium Therapeutics Inc., a company in operation since 1996 that
Trillium Therapeutics Inc. Raises Funds to Advance Urology Program Into Clinical Trillium Therapeutics Inc.'s Cancer Stem Cell Program to be Highlighted at
Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specialize.
iCo Therapeutics Inc., British Columbia. Trillium Therapeutics Inc., Québec. 2005. Innodia Inc., Québec. Variation Biotechnologies Inc., Ontario /Québec
Receiving the Ron Rice Business Award for Winston-Salem was Trillium Therapeutics, owned byJamie Huss, a massage therapist. The award
Trillium Therapeutics Inc. - Pharmaceuticals & Healthcare - Deals and therapies in the therapeutic areas of autoimmune disease, cancer,
13 Nov 2009 interest and/or other relationship with Medtronic, Advanced Bionics, Boston Scientific, Allergan, Pfizer, Celgene and Trillium Therapeutics.
Trillium Therapeutics Inc. Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical firm, acquired all assets of Arthron Ltd. Pty., a subsidiary of Australian
9.12. PanGenetics 116 9.13. PDL BioPharma 116 9.14. Perseis Therapeutics 117 9.15. Seattle Genetics 117 9.16. ToleRx 118 9.17. Trillium Therapeutics 119
18 Jan 2010 Canada and Australia are doing a do-sa-do (Topigen-Pharmaxis, YM-Cytopia), and Trillium Therapeutics signed an out-license to Biogen,
Trillium Therapeutics Inc. - Company Profile - Buyers' Guide.
27 Jul 2011 on an out-patient basis; Trillium Therapeutics: Trillium Therapeutics is developing an innovative treatment of interstitial cystitis, a chronic and
TORONTO, December 14/PRNewswire/ — Trillium Therapeutics Inc. (TTI), a Canadian biopharmaceutical company, announced today that it
Disclosures: Trillium Therapeutics Inc.: Consultant or Advisor. Gerald H. Jordan, MD Norfolk, VA Disclosures: American Board of Urology: Board Member, Officer,
Privacy Policy. Company Profile. Trillium Therapeutics Inc. Address: 96 Skyway Ave Toronto, ON M9W 4Y9. Telephone: (416) 595-0627. More Information
TORONTO, Dec. 15, 2011 /PRNewswire/ -Trillium Therapeutics Inc., a privately- held biopharmaceutical company developing proprietary and
2 Jun 2005 Ferring AS, Calyx Therapeutics, Boehringer Ingelheim, Novo Nordisk, Trillium Therapeutics, Inc., Hydra Biosciences and Schering Plough.
On behalf of the management and staff of Trillium Therapeutics Inc. we would like to express our thanks and gratitude to EastLink Telecom for their excellent
Home › Publications › News › Canada-Asia News Service › Trillium Therapeutics Inc. Press Release · Subscribe Print. Trillium Therapeutics Inc. Press Release
Medarex and Trillium Therapeutics Announce Collaboration to Develop Fully Human Antibody Therapeutics.
Small animal models for assessing immunomodulatory effects
Trillium Therapeutics is listed and edited by the users of BackgroundChecksWiki in Employer Directory. You can review and edit this record if you find anything
Trillium Therapeutics Inc.-Company Report - new market report released Trillium Therapeutics Inc.-Company Report.
Trillium Therapeutics Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Trillium Therapeutics Inc. (TTI) is a research-driven
【研究报告名称】：Trillium Therapeutics Inc.-Detailed Product Pipeline【价格】：750 购买方式：010-82600893 010-82601561/2/3.
In 1997, Dr. Levy was the co-founder of Trillium Therapeutics, a biotechnology company and served as the Chief Scientific Officer until 2002. In 2001 he became
A Sweet Beginning at Trillium Therapeutics, Winston-Salem, NC : Reviews and maps - Yahoo! Local, 336.577.6627. Get Ratings, Reviews, Photos and more on
Dr Moore is Chairman of Trillium Therapeutics Inc, a private Toronto-based biologics company; Asterion Limited, a Sheffield-based biologics company; and of
15, 2011 /PRNewswire/ -Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative biologic therapies, today
We will be hosting Dr. Bob Uger (Ph.D), VP of Research & Development (Trillium Therapeutics) at an industry seminar on Friday, November 26th. Dr. Uger
TORONTO, May 12 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised
iCo Therapeutics Inc., British Columbia. Inimex Pharmaceuticals, British Columbia. Innodia Inc., Quebec. Trillium Therapeutics Inc., Ontario. Variation
TTI 1612 Trillium Orphan Drug, EU, USA (inflammation).(Trillium Therapeutics Inc .)(Brief article) - Find R & D Focus Drug News articles.
View Trillium Therapeutics's recent news, press releases and events about new products, new hires, business development deals and customers..
Trillium Therapeutics Inc. Therapeutic Competitor Report contains detailed information on pipelines by phase and therapeutic indication as well as management
Medarex, Trillium Therapeutics develop antibodies on Strategic Transactions, Oct -01-2003.
Dr. Stiernholm is President and CEO as well as a director of Trillium Therapeutics , a privately held Canadian biopharmaceutical company, where he oversees
Stem Cell Therapeutics said the purpose of the restructuring is to focus its Most recently, he held positions with Trillium Therapeutics Inc. and
Le 12 janvier 2010, Trillium Therapeutics Inc., société biopharmaceutique fermée spécialisée en thérapies innovatrices soignant des conditions à médiation
Tuesday, Trillium Therapeutics Inc. signed a definitive license agreement with Biogen Idec (BIIB) granting the Biogen exclusive worldwide
This report provides information on the therapeutic development for 12.7 Trillium Therapeutics Inc. 23; 12.8 Bio Products Laboratory 23; 12.9
of building our industry, will create new paths and connections leading to real progress.” Dr. Nic Stiernholm, CEO Trillium Therapeutics
Current: Associate at Alba Biologics Group, Principal at Craig Binnie Consulting; Past: Director, Drug Development at Trillium Therapeutics, Inc., Director,
TORONTO - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced
TRILLIUM THERAPEUTICS INC. (Toronto, CA). Primary Class: 424/133.1. Other Classes: 424/130.1, 424/135.1, 424/152.1, 435/375, 514/44A
Current address for A. Khine: NOVX Systems Canada Inc., Markham L3R 6G3, Canada; S. Viau: Trillium Therapeutics Inc., Toronto M9W 4Y9,
About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as
Trillium Therapeutics Inc. (TTI), a Toronto-based biopharmaceutical company, announced that it has acquired all assets belonging to Arthron
Trillium Therapeutics' detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma
About Trillium: Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated
The Biotechgate Company Database provides a comprehensive overview on the life sciences industry with a special focus on biotechnology and medical
Represented: Trillium Therapeutics Inc. in connection with its preferred share financings. Represented: The VenGrowth Advanced Life Sciences Fund Inc. in
Biogen also announced that it has teamed up with Trillium Therapeutics, a Canadian biopharmaceutical company developing “innovative
Trillium Therapeutics Inc. is a private research and development company specializing in innovative therapies that restore balance to the
Send an email message to TRILLIUM THERAPEUTICS. TRILLIUM THERAPEUTICS is a Unclassified Establishments company located in Albany, Oregon.
Trillium Therapeutics, a biopharmaceutical company engaged in developing immune-based biologics, has appointed Michael Gresser to its
Trillium Therapeutics Inc. is a privately-held, venture-backed biopharmaceutical research and development company that was formerly known as
Companies > Trillium Therapeutics. Please log in to edit this profile Be the first to recommend Trillium Therapeutics! Log in
Trillium Therapeutics Inc. Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong Immunology focus, specializes i.
Trillium Therapeutics Inc. is a private biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as
Trillium Therapeutics Inc. - Pharmaceuticals & Healthcare, Deals and Alliances Profile: , published March 2011, pages 18, Trillium Therapeutics Inc.
Trillium Therapeutics Inc., Toronto, Ontario University Health Network, Toronto, Ontario. 12 words displayed of 77 words total. Get the Full Text.
Michael currently serves on the Boards of Aegera Therapeutics, Agrisoma, Natrix Separations, Praxim, Trillium Therapeutics, ViOptix and Viron Therapeutics Inc.
Medarex and Trillium Collaborate to Develop Human Antibodies. NJ, USA) and Trillium Therapeutics, Inc. (TTI, Trillium Therapeutics, Toronto
Trillium Therapeutics Raises C$1M. VentureWire, May 13, 2011, 91 words English. Biopharmaceuticals company Trillium Therapeutics Inc. said it has raised $1
Cancer treatments use a therapy that: 1) interferes with the
TORONTO, June 2 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) today announced that it has licensed exclusive worldwide rights to a series
Genentech signs deal for Trillium Therapeutics' technology on Strategic Transactions, Dec-01-2004.
TORONTO, Nov. 5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry
Trillium Therapeutics Inc. (TTI) is a private immune therapy research and development company founded in 1996. Our focus is to develop therapies that restore
Our goal is to develop therapies that restore balance to the immune system in conditions associated with abnormal and harmful immune responses.
Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has
A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative
Toronto, Ontario -- Pharmaceutical company Trillium Therapeutics has garnered $12 million in its series C venture capital investment round.
Trillium Therapeutics Inc. (TTI) announced that the Company has raised an additional $6 million, bringing the total of its Series A financing to
Free Online Library: Trillium Therapeutics Raises an Additional $6.0 Million to Close Series A Round at $13.5 million. by "PR Newswire";
Upside to this valuation remains from a 7% stake in Canadian biotech Trillium Therapeutics and from other projects being developed by Prima
Medarex and Trillium to develop antibody therapeutics. medarex, trillium, develop, antibody, therapeutics, usa-based, said.
Trillium Therapeutics Inc. is a research and development company specializing in innovative therapies that restore balance to the immune system in conditions
foursquare helps you keep up with friends, discover what's nearby, save money & unlock rewards. Get Started Now. Join foursquare to do that. Foursquare helps
Trillium Therapeutics Inc. is a privately held Research and Development company 12 /PRNewswire/ - Trillium Therapeutics Inc. granting the latter exclusive
2 PRNewswire - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that pr.
Toronto, ON - June 14, 2004 - Life sciences company Trillium Therapeutics says that Dr Marc Feldmann, a professor a
Trillium Therapeutics, a privately held biopharmaceutical company, has announced Michael Berendt and John Dietrich have joined its board as
Theratechnologies, Inc.; Tranzyme Pharma; Trillium Therapeutics;
He serves as a Director of Trillium Therapeutics Inc. He serves as a Director of Alethia BioTherapeutics, Inc. and Aegera Therapeutics Inc. He serves as a
Trillium Therapeutics will begin a phase I clinical trial of its experimental Working with an advisory group of urologists, Trillium has assembled
(1) Kennedy Institute of Rheumatology, Imperial College London, London, ROYAUME-UNI (2) Trillium Therapeutics, Inc, Toronto, Ontario, CANADA
Contacts at Trillium Therapeutics Inc., part of Biotechnology industry in Toronto, ON.
Trillium Therapeutics Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the
This report includes Trillium Therapeutics, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets,
Trillium Therapeutics Inc. (Toronto, Canada) has patented methods and compositions for regulating immunity. For enhancing an immune
Uger , Marni D. OptiMol Drug Discovery Division, Toronto, Canada. Uger , Robert A. Uger , R. A.. Uger , Robert, Trillium Therapeutics Inc. Toronto, Canada
Dr. Underdown's past and current board positions include: ID Biomedical, Trillium Therapeutics, Cytochroma Inc., Argos Therapeutics, Nysa Membrane
Consultant/Advisor: Philip M. Hanno, Astellas(C), Lilly(C), Watson(C), Taris(C), Trillium Therapeutics Inc.(C), Allergan(C), Pfizer(C); J. Quentin
Recently, Dr. Barber served on the Board of Directors of Inimex Pharmaceuticals and Trillium Therapeutics. Dr. Barber obtained his Ph.D. in Medical Biophysics
Trillium Therapeutics Inc. Product Pipeline Review Q4 2010 Summary Assess the growth potential of Trillium Therapeutics Inc. in its therapy areas of
Canadian Association of Naturopathic Doctors Vivosonic. Maxxam Analytics Trillium Therapeutics Ontario College of Physiotherapists Transition Therapeutics
5 /PRNewswire/ - Trillium Therapeutics Inc., a privately held biopharmaceutical company, announced today that industry veterans Dr. Michael
Trillium Therapeutics Inc. - US patent applications assigned to Trillium Therapeutics Inc..
Chronos Therapeutics was formed in 2009 with the aim of pursuing Chief Executive, Chairman of Trillium Therapeutics, joining the Board of Directors.
Trillium Therapeutics, Inc., a biopharmaceutical company developing innovative immune-based biologics, announced that it has entered into a
Trillium has since maintained the relationship with the Burnet Institute on this project and For more information on Trillium Therapeutics please see the website
Dr. Lavoie is currently on the boards of Axela, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics. Her prior experience includes
2011 “AF Partners” Visionary Circle $5000 +. Channelred Graphics House/ John Ruth Trillium Therapeutics/ Jamie Huss James Gross Swiftwater Media/Gregg
Trillium Therapeutics Inc.-Detailed Product Pipeline Trillium Therapeutics Inc.- Detailed Product Pipeline provides up to date insight into
Trillium Therapeutics Inc., Deals Summary, 2004 to 2010 20. Trillium Trillium Therapeutics Enters Into Licensing Agreement With Biogen Idec 21. Trillium
Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, announced that it has entered
Industry, Pharmaceutical. Company Description, Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus,
Trillium Therapeutics develops bio-pharmaceuticals and specializes in the treatment of immune-mediated disorders. If pharmaceuticals or
director of Waters Corporation and Trillium Therapeutics Inc. and has previously served on the board of directors of Onyx Pharmaceuticals,
Name: